Epigenetic regulation of apoptosis and cell cycle in osteosarcoma.
The role of genetic mutations in the development of osteosarcoma, such as alterations in p53 and Rb, is well understood. However, the significance of epigenetic mechanisms in the progression of osteosarcoma remains unclear and is increasingly being investigated. Recent evidence suggests that epigenetic alterations such as methylation and histone modifications of genes involved in cell cycle regulation and apoptosis may contribute to the pathogenesis of this tumor. Importantly, understanding the molecular mechanisms of regulation of these pathways may give insight into novel therapeutic strategies for patients with osteosarcoma. This paper serves to summarize the described epigenetic mechanisms in the tumorigenesis of osteosarcoma, specifically those pertaining to apoptosis and cell cycle regulation.
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Krithi
K
Rao-Bindal
Eugenie S
ES
Kleinerman
Cancer. 2006 Apr 1;106(7):1602-9
16502411
Clin Orthop Relat Res. 1991 Sep;(270):271-7
1884549
Cancer Res. 2001 Sep 15;61(18):6688-92
11559536
Nature. 1991 Jun 6;351(6326):453-6
2046748
Cancer Res. 2001 Oct 1;61(19):7034-8
11585730
Histol Histopathol. 2009 Sep;24(9):1105-11
19609857
Am J Hum Genet. 1991 May;48(5):880-8
1673287
Cancer Res. 1994 Jun 1;54(11):3042-8
8187094
Genes Dev. 2004 Jul 1;18(13):1592-605
15231737
Curr Opin Genet Dev. 2002 Apr;12(2):142-8
11893486
Cancer Res. 2001 May 15;61(10):3877-81
11358799
Oncogene. 2001 Nov 8;20(51):7573-7
11709729
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3674-8
14506157
Cancer Res. 1995 Nov 15;55(22):5187-90
7585571
Oncol Rep. 2003 Jul-Aug;10(4):897-901
12792742
Genes Dev. 2008 Jun 15;22(12):1662-76
18559481
Cancer Res. 1990 Dec 15;50(24):7950-4
2253237
Oncogene. 2001 Mar 22;20(12):1509-18
11313894
Toxicology. 2010 Jan 12;267(1-3):70-9
19879315
Cancer Res. 2007 Mar 15;67(6):2800-8
17363602
Oncogene. 2006 Aug 28;25(38):5220-7
16936740
Clin Orthop Relat Res. 2006 Jan;442:216-22
16394764
Cell. 2002 Jun 28;109(7):801-6
12110177
Cell. 2005 Nov 4;123(3):437-48
16269335
Pediatr Hematol Oncol. 1992 Apr-Jun;9(2):125-37
1524989
Cell Death Differ. 2010 Aug;17(8):1238-43
20467440
J Med Invest. 2004 Aug;51(3-4):146-53
15460900
Int J Cancer. 1999 Oct 22;84(5):489-93
10502725
J Pediatr Hematol Oncol. 2003 May;25(5):362-7
12759621
Cell. 2007 Feb 23;128(4):683-92
17320506
Cancer Res. 2002 Jun 15;62(12):3498-502
12067994
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11851-6
18697945
Mol Cancer Ther. 2009 Jun;8(6):1409-20
19509247
Mol Cell. 2005 Jun 10;18(6):637-50
15949439
Chest. 1992 Mar;101(3 Suppl):19S-20S
1541189
Science. 1984 Mar 9;223(4640):1028-33
6320372
Nature. 2000 Jan 6;403(6765):41-5
10638745
Cancer Res. 2001 Oct 1;61(19):7277-81
11585766
Prog Cell Cycle Res. 1995;1:9-19
9552350
Curr Opin Cell Biol. 2003 Apr;15(2):172-83
12648673
Science. 1991 Jul 5;253(5015):49-53
1905840
Cancer Res. 2002 Jul 1;62(13):3698-701
12097277
Cancer Cell. 2004 Oct;6(4):387-98
15488761
J Clin Oncol. 1994 May;12(5):925-30
8164043
Cancer Genet Cytogenet. 1996 Feb;86(2):136-42
8603340
Oncologist. 2004;9(4):422-41
15266096
Cancer J. 2005 Jul-Aug;11(4):294-305
16197719
Cancer Invest. 2001;19(3):292-315
11338887